A Collaborative Project with the Vancouver Prostate Centre Aims to Improve Patient Selection for Clinical Trials

Date Posted: 
2010-10-29

The Vancouver Prostate Centre today announced a one-year collaborative project with Novartis Pharmaceutical Corporation. The project will use cutting-edge technology to identify and validate the molecular targets that predict cancer sensitivity or insensitivity to specific inhibitors. Ultimately these insights may enable clinicians to more accurately select patients who are likely to benefit from a particular clinical trial.

Using its unique expertise in prostate cancer, advanced genomics and bioinformatics, the Vancouver Prostate Centre will delve deeper into the comprehensive genetic analysis of 1000 cell lines and internal data that that have been developed by the Novartis Oncology Translational Medicine group. The data identifies the growth inhibitory activity of numerous compounds in approximately 500 of these cell lines.

“We are pleased to be working with Novartis to potentially add value to the data they’ve already generated by uncovering new sensitivity signatures and pathways,” says Dr. Martin Gleave, director of the Vancouver Prostate Centre.

Specifically, the genetic, molecular, and pharmacologic data for the compounds will be provided to Dr. Colin Collins, Director of the Laboratory for Advanced Genome Analysis at the Vancouver Prostate Centre, for his team to derive and validate sensitivity signatures. The ultimate goal is to use such signatures to better design clinical trials, improve patient selection and maximize the benefits of potential drug treatments by understanding patient responses.

“Our Laboratory for Advanced Genome Analysis at the Vancouver Prostate Centre, headed by Dr. Collins, represents a major initiative in computer science and bioinformatics expertise and equipment and significantly augments and complements our substantial microarray and sequencing services and allows us to take on this type of specialized analysis," Dr. Gleave adds.

A World Class Centre

The Vancouver Prostate Centre (VPC) has a track record of success that has earned it a reputation as one of the world’s most respected cancer facilities. It is a National Centre of Excellence and a designated Centre of Excellence for Commercialization and Research.

Events

Conference Flyer Page 1

Breast & Prostate Cancer half-day virtual conference: Saturday, September 18th, 2021

The What you Need to Know for Your Patients Post Breast & Prostate Cancer Conference, taking place online on Saturday, September 18th, 2021 from 8:00am – 1:30pm, is an accredited virtual half-day conference focusing on screening, treatment, side-effect management & emerging new therapies for breast & prostate cancer patients. Click here for more information and to register. 

Dr. Peter Black, team captain

Terry Fox Run fundraiser: September 19th, 2021

The 41st Annual Terry Fox Run is taking place on Sunday September 19, 2021. If you are able, please consider donating to our team (tax receipts issued), raising funds for the Terry Fox Foundation's ground-breaking cancer research. 

Employment

Work at the Vancouver Prostate Centre

Wednesday, September 8, 2021

Recent publication proposes a potential new therapeutic approach to treatment-resistant prostate cancer

Tuesday, August 3, 2021

Dr. Cherkasov receives 2021 Faculty of Medicine Distinguished Achievement Award

Dr. Cherkasov